Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
-
- COOPER ROBIN D. G.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- SNYDER NANCY J.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- ZWEIFEL MARK J.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- STASZAK MICHAEL A.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- WILKIE STEPHEN C.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- NICAS THALIA I.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- MULLEN DEBORAH L.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- BUTLER THOMAS F.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- RODRIGUEZ MICHAEL J.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- HUFF BRET E.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
-
- THOMPSON RICHARD C.
- Infectious Diseases Research, Lilly Research Laboratories, Eli Lilly and Company
書誌事項
- 公開日
- 1996
- 資源種別
- journal article
- DOI
-
- 10.7164/antibiotics.49.575
- 公開者
- 公益財団法人 日本感染症医薬品協会
この論文をさがす
説明
Reductive alkylation of the A82846 family of glycopeptide antibiotics has the potential of producing seven products. N-Alkylation of the disaccharide amino function can be accomplished selectively, and offers the greatest increase in antibacterial activity. Products resulting from N-alkylation of LY264826 (A82846B) provide the most potent derivatives as compared to other members of this class of antibiotics. Two of these derivatives, LY307599 and LY333328 are approximately 500 times more active than vancomycin against vancomycin-resistant enterococci.
収録刊行物
-
- The Journal of Antibiotics
-
The Journal of Antibiotics 49 (6), 575-581, 1996
公益財団法人 日本感染症医薬品協会
